文献速递浆细胞疾病造血干细胞移植与细胞治疗血栓与止血

BCMA/CS1双特异性CAR-T细胞治疗多发性骨髓瘤并发血小板减少:一例病例报告及文献复习

[BCMA/CS1 bispecific CAR-T cell therapy for multiple myeloma complicated with thrombocytopenia: a case report and literature review].
PubMed 文献 · Zhonghua Xue Ye Xue Za Zhi · 2024-01-01

回顾性分析1例72岁轻链κ型多发性骨髓瘤(R-ISS Ⅱ期)患者接受BCMA/CS1双靶点CAR-T细胞临床试验(NCT04662099)后出现持续≥3级血小板减少的临床资料,并检索中英文文献。患者回输低剂量CAR-T细胞2个月达完全缓解,第8天发生3级细胞因子释放综合征,随后严重消化道出血及血小板减少,接受利妥昔单抗治疗后血小板逐渐回升,后失访。共检索到英文文献24篇、中文文献8篇。

要点

  • BCMA/CS1双靶点CAR-T细胞治疗后可持续≥3级血小板减少,伴巨核细胞生成障碍。
  • 本例回输后第8天发生3级细胞因子释放综合征,随后出现严重消化道出血。
  • 利妥昔单抗治疗后本例血小板逐渐回升,疗效显著。

核心结论

  • CAR-T细胞治疗相关血小板减少表现为血小板减少和巨核细胞生成障碍。
  • 持续性血小板减少增加出血风险。
  • 应用CD20单抗及支持治疗可有效改善血小板减少。

研究设计与样本

  • 回顾性收集2021年6月于华中科技大学同济医学院附属协和医院血液科接受BCMA/CS1双靶点CAR-T细胞治疗的1例多发性骨髓瘤患者的临床资料并分析。
  • 以「嵌合抗原受体T细胞治疗」「血小板减少」「chimeric antigen receptor-T cell therapy」「CAR-T」「thrombocytopenia」「BCMA」「CS1」为检索词,检索自建库至2024年11月中文数据库(中国知网数据库、万方数据库)及PubMed数据库中的文献并进行文献复习。
  • 共检索到相关英文文献24篇,中文文献8篇。

主要发现

  • 患者男,72岁,于当地医院诊断为轻链κ型多发性骨髓瘤(R-ISS Ⅱ期),治疗周期较长,多次调整化疗方案后疾病控制不佳。
  • 经筛选患者符合BCMA/CS1双靶点CAR-T细胞临床试验(NCT04662099)纳入标准,回输低剂量CAR-T细胞2个月后达到完全缓解。
  • CAR-T细胞回输后第8天患者发生3级细胞因子释放综合征,随后出现严重消化道出血症状及持续≥3级血小板减少,伴促血小板生成素水平显著升高,骨髓细胞学未见巨核细胞。
  • 患者接受利妥昔单抗治疗后血小板逐渐回升,疗效显著;后因持续营养不良伴消瘦转入消化科治疗后失访。

临床怎么用

  • 作者结论认为,CAR-T细胞治疗相关血小板减少表现为血小板减少和巨核细胞生成障碍,持续性血小板减少增加出血风险,应用CD20单抗及支持治疗可有效改善血小板减少。

局限性

  • 本文为单例病例报告,患者转入消化科治疗后失访。
  • 原文未报告其他局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To investigate the clinical manifestations, diagnostic and therapeutic strategies, for thrombocytopenia after BCMA/CS1 bispecific chimeric antigen receptor T-cell (CAR-T cell) therapy in patients with multiple myeloma. Methods: Retrospective collection and analysis were conducted on the clinical data of a patient with multiple myeloma who received BCMA/CS1 bispecific CAR-T cell therapy in the Hematology Department of Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, in June 2021. To review the literature, Chinese databases (CNKI, Wanfang Database) and PubMed were searched from their inception up to November 2024 using the keywords "chimeric antigen receptor T-cell therapy", "thrombocytopenia", "CAR-T", "BCMA", and "CS1" . Results: A 72-year-old male patient was diagnosed with light chain κ-type multiple myeloma (R-ISS stage Ⅱ) in a local hospital and had a prolonged treatment course with poor disease control despite multiple adjustments of chemotherapy regimens. The patient met the inclusion criteria for the BCMA/CS1 dual-target CAR-T cell clinical trial (NCT04662099) and achieved complete remission two months after receiving a low dose of CAR-T cells. On the 8th day after CAR-T cell infusion, the patient developed grade 3 cytokine release syndrome, followed by severe gastrointestinal bleeding and persistent grade ≥3 thrombocytopenia, accompanied by a significant increase in thrombopoietin levels, with no megakaryocytes observed in bone marrow cytology. After treatment with rituximab, significant improvement was observed with platelet count gradually increased. However, the patient experienced persistent malnutrition and cachexia, and transferred to the gastroenterology department, after which follow-up was lost. A total of 24 relevant English articles and 8 Chinese articles were retrieved from the literature search. Conclusion: CAR-T cell therapy associated thrombocytopenia is characterized by thrombocytopenia and megakaryocyte production disorders. Persistent thrombocytopenia increases the risk of bleeding, and the use of CD20 monoclonal antibodies and supportive therapy can effectively improve thrombocytopenia. 目的: 探讨BCMA/CS1双靶点嵌合抗原受体T细胞(CAR-T细胞)治疗多发性骨髓瘤后并发血小板减少的临床表现和诊疗策略。 方法: 回顾性收集2021年6月于华中科技大学同济医学院附属协和医院血液科接受BCMA/CS1双靶点CAR-T细胞治疗的1例多发性骨髓瘤患者的临床资料并进行分析。以"嵌合抗原受体T细胞治疗"、"血小板减少"、"chimeric antigen receptor-T cell therapy"、"CAR-T"、"thrombocytopenia"、"BCMA"、"CS1"为检索词,检索自建库至2024年11月中文数据库(中国知网数据库、万方数据库)及Pubmed数据库中的文献并进行文献复习。 结果: 患者,男,72岁,于当地医院诊断为轻链κ型多发性骨髓瘤(R-ISS Ⅱ期)。患者治疗周期较长,多次调整化疗方案后疾病控制不佳。经筛选患者符合BCMA/CS1双靶点CAR-T细胞临床试验(NCT04662099)纳入标准,回输低剂量CAR-T细胞2个月后患者达到完全缓解。CAR-T细胞回输后第8天患者发生3级细胞因子释放综合征,随后出现严重消化道出血症状及持续≥3级血小板减少,伴促血小板生成素水平显著升高,骨髓细胞学未见巨核细胞。患者接受利妥昔单抗治疗后血小板逐渐回升,疗效显著。后因患者持续营养不良伴消瘦,转入消化科治疗后失访。文献检索共检索到相关英文文献24篇,中文文献8篇。 结论: CAR-T细胞治疗相关血小板减少表现为血小板减少和巨核细胞生成障碍,持续性血小板减少增加出血风险,应用CD20单抗及支持治疗可有效改善血小板减少。.

来源:Zhonghua Xue Ye Xue Za Zhi,查看原文。版权归原作者所有。

引用

  1. Li PR, Li YY, Du MY, et al. [BCMA/CS1 bispecific CAR-T cell therapy for multiple myeloma complicated with thrombocytopenia: a case report and literature review]. Zhonghua Xue Ye Xue Za Zhi. 2024. PMID: 40032341. doi:10.3760/cma.j.cn121090-20241202-00524

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。